Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice.
We developed a mouse model of acute encephalopathy induced by verotoxin 2 variant (VT2v)-producing Escherichia coli. Three-week-old mice were inoculated intragastrically with approximately 10(10) CFU of E. coli O157:H- strain E32511/HSC and simultaneously given an intraperitoneal injection of mitomycin (MMC; 2.5 mg/kg). Drinking water containing 5 g of streptomycin sulfate per liter was given ad libitum from 3 days before the infection. From 1 to 2 days after bacterial inoculation, clinical features including weight loss, weakness, and flaccid paralysis of the extremities developed, usually culminating in death within 4 days. Diarrhea was not observed during the course of disease. No mice died in the absence of streptomycin or MMC treatment for 2 weeks after the oral bacterial infection. Judging from the clinical course and the biochemical and histological examination, the cause of death was not likely to be attributable to renal failure or to a side effect of MMC. To better understand the cause of death, we examined the brain cortex and spinal cord of the moribund mice by electron microscopy. Mice showing mortal symptoms were given horseradish peroxidase intravenously. The tracer was present in the endothelial basal lamina, in the surrounding extracellular spaces, and even in the neuron fibers of the brain cortex. Furthermore, immunoreactivity of VT2v, proved by the use of rabbit anti-VT2 serum, was localized selectively in the damaged myelin sheaths of neuron fibers which were accompanied by edematous axons in the brain cortex and spinal cord. These findings strongly suggest that VT2v is toxic to both endothelial cells and neurons in the central nervous system and subsequently causes fatal acute encephalopathy.
Fujii
J
J
Department of Microbiology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Kita
T
T
Yoshida
S
S
Takeda
T
T
Kobayashi
H
H
Tanaka
N
N
Ohsato
K
K
Mizuguchi
Y
Y
D000208:Acute Disease; D000818:Animals; D001427:Bacterial Toxins / Q000032:analysis / Q000633:toxicity*; D001812:Blood-Brain Barrier; D001927:Brain Diseases / Q000209:etiology*; D004305:Dose-Response Relationship, Drug; D004927:Escherichia coli Infections / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D016253:Microscopy, Immunoelectron; D008937:Mitomycins / Q000627:therapeutic use*; D022622:Shiga Toxin 1; D013307:Streptomycin / Q000627:therapeutic use
D001427:Bacterial Toxins; D008937:Mitomycins; D022622:Shiga Toxin 1; D013307:Streptomycin